Taiwan’s only locally produced vaccine, Medigen, faced criticism when it was approved for Emergency Use Authorization, or EUA, ahead of completing Phase III trials. In an exclusive interview with Taiwan+, Medigen’s president Charles Chen tackles the criticism head on and explains how very few COVID cases in Taiwan triggered an entirely new way of approving vaccines.